Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, and Urothelial Cancers

NCT07545122 is registered in ClinicalTrials.gov with Context Therapeutics Inc. as lead sponsor.

NCT NCT07545122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07545122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, and Urothelial Cancers
Lead sponsor
Context Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 30, 2026
Completion date
January 31, 2030
Enrollment
162 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, triple negative breast cancer (tnbc), urothelial cancer